Methods for identifying patients with anemia, distinguishing thalassemia-trait anemia from iron-deficiency anemia, and identifying pre-anemic patients several weeks before anemia becomes clinically detectable. Also, methods for detecting blood doping in athletes and for optimizing therapy with erythropoiesis stimulating agents or iron supplementation. Computer-readable storage devices and systems, e.g., for use in the described methods.

A component measurement device for measuring a component of interest in blood based on an optical property of a mixture containing a pigmentary component colored by a color reaction between the component of interest in the blood and a reagent, the component measurement device including: an absorbance obtaining unit configured to obtain a measured value of absorbance of the mixture at a measuring wavelength; and an absorbance correction unit configured to correct the measured value of absorbance of the mixture at the measuring wavelength based on information on scattered light and a ratio between reduced hemoglobin and oxygenated hemoglobin in erythrocytes.

A method for evaluating adverse reaction of sesquiterpenoids in zedoary turmeric oil is performed successively according to the following steps: (1) preparing a hemoglobin (Hb) solution and a to-be-determined solution; (2) taking Hb solutions with a same volume and respectively adding the same volume of the to-be-determined solution or normal saline thereto, mixing well and standing; (3) determining absorbance with a microplate reader, and comparing the absorbance of a to-be-determined solution group with the absorbance of a normal saline group to obtain a value r; wherein if r>1.5, then the result indicates that the concentration of the to-be-determined solution has a risk of causing dyspnea; wherein,

[00001]$r=\frac{\mathrm{OD}}{{\mathrm{OD}}_{\mathrm{Hb}}};$

in the formula, OD is an absorbance at 280 nm wavelength of the to-be-determined solution after interacting with Hb; OD.sub.Hb, is an absorbance at 280 nm wavelength of a blank control of normal saline after interacting with Hb.

In certain aspects, the present invention provides methods for dosing a patient with an ActRIIb antagonist and methods for managing patients treated with an ActRIIb anatagonist. In certain aspects, the methods involve measuring one or more hematologic parameters in a patient.

A method is disclosed comprising lysing the red blood cells of a whole blood sample, oxidizing the free hemoglobin in the lysed sample, and cleaving FVH from the hemoglobin A1C to form an electrochemical test solution. In one aspect, a first portion of the electrochemical test solution is reacted with fructosyl peptide oxidase and a reduced ruthenium mediator to form a first reaction product. A first electrical property of the first reaction product is measured, the measurement being indicative of hemoglobin A1C in the blood sample. In another aspect, a second portion of the electrochemical test solution is reacted with ferrocyanide to form a second reaction product. A second electrical property of the second reaction product is measured, the measurement being indicative of total hemoglobin in the blood sample. Hemoglobin A1C, total hemoglobin, and % HbA1C are determined based on the first and second electrical properties. Also provided are systems and components useful in performing the disclosed methods.

From a chromatogram obtained by subjecting a blood sample to liquid chromatography, the ratio of a peak value of an HbF peak to a peak value of the entire hemoglobin peak is calculated, and the ratio is multiplied by a predetermined factor, to calculate a corrected value of the HbF peak with respect to the entire hemoglobin peak.

A reagent for use in the measurement of hemoglobins by liquid chromatography, the reagent comprising a nonionic surfactant selected from the group consisting of: (i) polyoxyethylene (10) decyl ether; (ii) polyoxyethylene (6) 2-ethylhexyl ether; (iii) polyoxyethylene (9) isodecyl ether; (iv) polyoxyethylene (10) nonyl ether; (v) polyoxyethylene (16) isostearyl ether; (vi) polyoxyethylene (20) behenyl ether; and (vii) polyoxyethylene (20) polyoxypropylene (6) decyltetradecyl ether.

The invention concerns a method for determining, by flow cytometry, the hemoglobin F (HbF) content of each erythroid cell of a set of erythroid cells. This method applies in particular to determining the HbF content of each red blood cell of a set of red blood cells. The invention also concerns a method for determining the amount of red blood cells transfused into a patient and for monitoring the therapeutic efficacy of a treatment for sickle cell disease or β-thalassemia.

The present invention provides an anti-human hemoglobin monoclonal antibody or an antibody kit for specifically detecting and measuring a hemoglobin-haptoglobin complex in a sample with ease, and an insoluble carrier particle to which the monoclonal antibody is immobilized, and a measurement reagent and a measurement method for specifically detecting and measuring a hemoglobin-haptoglobin complex in a sample using the same. The anti-human hemoglobin monoclonal antibody of the present invention does not react to free hemoglobin or free haptoglobin which is not formed in a complex, but specifically reacts to a hemoglobin-haptoglobin complex when the antibody is immobilized to an insoluble carrier particle and used.

The invention concerns a method for determining, by flow cytometry, the hemoglobin content of each erythroid cell of a set of erythroid cells. This method applies in particular to determining the hemoglobin content of each red blood cell of a set of red blood cells. The invention also concerns a method for determining the amount of red blood cells transfused into a patient and for monitoring the therapeutic efficacy of a treatment for sickle cell disease or β-thalassemia.